These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 26333375)

  • 21. Impact of different stent alloys on human vascular response to everolimus-eluting stent: an optical coherence tomography study: the OCTEVEREST.
    Guagliumi G; Capodanno D; Ikejima H; Bezerra HG; Sirbu V; Musumeci G; Fiocca L; Lortkipanidze N; Vassileva A; Tahara S; Valsecchi O; Costa MA
    Catheter Cardiovasc Interv; 2013 Feb; 81(3):510-8. PubMed ID: 22431208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial.
    Sotomi Y; Onuma Y; Dijkstra J; Miyazaki Y; Kozuma K; Tanabe K; Popma JJ; de Winter RJ; Serruys PW; Kimura T
    Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):59-66. PubMed ID: 28158421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
    Shiratori Y; Brugaletta S; Alvarez-Contreras L; Azpeitia Y; Ospino N; Gaido S; Delahanty A; Santos A; Martin-Yuste V; Masotti M; Serruys PW; Windecker S; Sabaté M
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E428-36. PubMed ID: 23441068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of neointimal coverage between ultrathin biodegradable polymer-coated sirolimus-eluting stents and durable polymer-coated everolimus-eluting stents: 6 months optical coherence tomography follow-up from the TAXCO study.
    Abhyankar A; Abizaid A; Chamié D; Rathod M
    Catheter Cardiovasc Interv; 2021 Feb; 97(3):423-430. PubMed ID: 32243050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of vascular responses after different types of second-generation drug-eluting stents implantation detected by optical coherence tomography.
    Ohtani H; Kimura S; Sugiyama T; Hishikari K; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Kojima K; Sagawa Y; Hikita H; Ashikaga T; Takahashi A; Isobe M
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):177-186. PubMed ID: 27761750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial.
    Iñiguez A; Chevalier B; Richardt G; Neylon A; Jiménez VA; Kornowski R; Carrie D; Moreno R; Barbato E; Serra-Peñaranda A; Guiducci V; Valdés-Chávarri M; Yajima J; Wijns W; Saito S;
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):175-184. PubMed ID: 31033154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Difference in vascular response between sirolimus-eluting- and everolimus-eluting stents in ostial left circumflex artery after unprotected left main as observed by optical coherence tomography.
    Fujino Y; Attizzani GF; Tahara S; Naganuma T; Takagi K; Yabushita H; Wang W; Tanaka K; Matsumoto T; Kawamoto H; Yamada Y; Amano S; Watanabe Y; Warisawa T; Sato T; Mitomo S; Kurita N; Ishiguro H; Hozawa K; Tsukahara T; Motosuke M; Bezerra HG; Nakamura S; Nakamura S
    Int J Cardiol; 2017 Mar; 230():284-292. PubMed ID: 28065691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
    Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T
    Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary Syndromes: Insights From Optical Coherence Tomography Imaging Analysis.
    Jaguszewski M; Aloysius R; Wang W; Bezerra HG; Hill J; De Winter RJ; Karjalainen PP; Verheye S; Wijns W; Lüscher TF; Joner M; Costa M; Landmesser U
    JACC Cardiovasc Interv; 2017 Mar; 10(5):489-499. PubMed ID: 28279316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of patients treated with a biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stents after rotational atherectomy.
    Mankerious N; Hemetsberger R; Traboulsi H; Toelg R; Abdel-Wahab M; Richardt G; Allali A
    Clin Res Cardiol; 2021 Oct; 110(10):1574-1585. PubMed ID: 33861369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions.
    Dan K; Garcia-Garcia HM; Kolm P; Windecker S; Saito S; Kandzari DE; Waksman R
    Circ Cardiovasc Interv; 2020 Sep; 13(9):e009189. PubMed ID: 32895004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioresorbable polymer-coated thin strut sirolimus-eluting stent vs durable polymer-coated everolimus-eluting stent in daily clinical practice: Propensity matched one-year results from interventional cardiology network registry.
    Gasior P; Gierlotka M; Szczurek-Katanski K; Osuch M; Gnot R; Hawranek M; Gasior M; Polonski L
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):E362-E368. PubMed ID: 30298545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of late-acquired stent malapposition of drug eluting stents with second generation permanent and biodegradable polymer coatings-A prospective, randomized comparison using optical coherence tomography.
    Roth C; Gangl C; Dalos D; Delle-Karth G; Neunteufl T; Berger R
    J Interv Cardiol; 2018 Dec; 31(6):780-791. PubMed ID: 30479028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serial randomized comparison of strut coverage of everolimus- and first-generation sirolimus-eluting stents.
    Kim JS; Kim JH; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Can J Cardiol; 2015 Jun; 31(6):723-30. PubMed ID: 25882337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial.
    Moreu J; Moreno-Gómez R; Pérez de Prado A; García Del Blanco B; Trillo R; Pinar E; Molina E; Zueco J; Merchán A; Díaz-Fernández JF; Amat I
    EuroIntervention; 2019 Dec; 15(12):e1081-e1089. PubMed ID: 31310239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography.
    Choi HH; Kim JS; Yoon DH; Hong KS; Kim TH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Mar; 28(3):491-7. PubMed ID: 21442265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-year vascular responses to drug-eluting stents with biodegradable polymer versus durable polymer: An optical coherence tomography sub-study of the NEXT.
    Katayama Y; Kubo T; Akasaka T; Ino Y; Kimura K; Okura H; Shinke T; Igarashi K; Kadota K; Kozuma K; Tanabe K; Nakagawa Y; Muramatsu T; Morino Y; Kimura T;
    J Cardiol; 2017 Dec; 70(6):530-536. PubMed ID: 28536015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study.
    Kim SJ; Lee H; Cho JM; Park CB; Kim W; Kato K; Yonetsu T; Kim CJ; Jang IK
    Coron Artery Dis; 2013 Aug; 24(5):431-9. PubMed ID: 23722649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.